AlzeCure Pharma logo

Loading..
Svenska
Svenska
  • News
    News
      • Upcoming events
      • Subscribe
  • About us
    About us
      • AlzeCure Pharma in brief
      • Mission, vision & strategy
      • A word from the CEO
      • Organization
        • Management team
        • Board of directors
        • Founders
        • Scientific advisors
        • Collaborations and Partnership
      • History
      • Career
        • Open positions
  • Research & development
    Research & development
      • Project portfolio
      • NeuroRestore
      • Alzstatin
      • Alzheimer’s disease
      • Depression
      • Painless
        • ACD440
        • TrkA-NAM
      • Pain
        • Erythromelalgia
      • Small molecules
      • Publications
      • The patients story
  • Governance
    Governance
      • Corporate Governance Reports
      • General meeting
        • General meetings
      • Nomination Committee
      • Board of directors
      • Management team
      • Remuneration
      • Auditors
      • Articles of association
  • Investors
    Investors
      • Rights issue 2025
      • Capital Markets Day 2023
      • AlzeCure Pharma on First North Premier Growth Market
        • Certified Adviser
      • Prospectuses
      • The share
        • Trading information
        • Sharecapital development
        • Dividend policy
        • Ownership structure
        • Insiders
        • Analyst Coverage
      • Financial reports
      • Financial calendar
      • Presentations and Interviews
      • Press releases
  • Media
    Media
      • Press releases
      • Presentations and Interviews
      • Video gallery
      • Image bank
        • Board of directors
        • Management
        • Founders
        • Logotype
      • Financial calendar
      • Subscribe
      • Contact
  • Subscribe
  • Contact
    Contact
      • Office
      • Investors
      • Media

Press releases

All pressreleases
  • Regulatory press releases
  • Other press releases
2019
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2018
  • All years
December 20, 2019

AlzeCure initiates clinical trial with ACD856

November 15, 2019

AlzeCure publishes its interim report for January – September 2019

August 22, 2019

AlzeCure publishes its interim report for January – June 2019

May 22, 2019

Report from the annual general meeting of AlzeCure Pharma on 22 May 2019

May 3, 2019

AlzeCure changes direction for its drug candidate ACD855 within the NeuroRestore platform

April 29, 2019

AlzeCure publishes its interim report for Q1 2019

April 15, 2019

AlzeCure publishes its Annual Report for 2018

March 25, 2019

AlzeCure to present at International scientific conference

March 20, 2019

AlzeCure initiates new drug project within pain

  • Media
    • Press releases
    • Presentations and Interviews
    • Video gallery
    • Image bank
      • Board of directors
      • Management
      • Founders
      • Logotype
    • Financial calendar
    • Subscribe
    • Contact
Mikael Widell
Mikael Widell
Head of Communications and IR
[email protected]
+46 703 11 99 60
News
  • Upcoming events
  • Subscribe
About us
  • AlzeCure Pharma in brief
  • Mission, Vision & Strategy
  • A word from the CEO
  • Organization
  • Career
  • History
Research & development
  • Project portfolio
  • NeuroRestore
  • Alzstatin
  • Alzheimer’s disease
  • Depression
  • Painless
  • Pain
  • Small molecules
  • Publications
  • The patients story
Governance
  • Corporate Governance Reports
  • General meeting
  • Nomination Committee
  • Board of directors
  • Management team
  • Remuneration
  • Auditors
  • Articles of association
Investors
  • Rights issue 2025
  • Capital Markets Day 2023
  • AlzeCure Pharma on First North Premier Growth Market
  • Prospectuses
  • The share
  • Financial reports
  • Financial calendar
  • Presentations and Interviews
  • Press releases
  • Subscribe
  • Contact
Media
  • Press releases
  • Presentations and Interviews
  • Video gallery
  • Image bank
  • Financial calendar
  • Subscribe
  • Contact
Contact
  • Office
  • Investors
  • Media

AlzeCure Pharma AB, Hälsovägen 7,  SE-141 57 Huddinge, Sweden. Registration number: 559094-8302.

  • Follow us on LinkedIn
  • About cookies
  • Privacy policy for Alzecure Pharma